Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma.

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Abstract Text:

Tobias Klatte,David B Seligson,Stephen B Riggs,John T Leppert,Maria K Berkman,Mark D Kleid,Hong Yu,Fairooz F Kabbinavar,Allan J Pantuck,Arie S Belldegrun,Tobias Klatte,David B Seligson,Stephen B Riggs,John T Leppert,Maria K Berkman,Mark D Kleid,Hong Yu,Fairooz F Kabbinavar,Allan J Pantuck,Arie S Belldegrun,

PURPOSE: Hypoxia-inducible factor-1alpha (HIF-1alpha) plays an important role in tumoral adaptation to hypoxic conditions by serving as a transcription factor for several crucial proteins, including vascular endothelial growth factor and carbonic anhydrase IX (CAIX). Here, we evaluated the significance of HIF-1alpha in renal cell carcinoma (RCC). EXPERIMENTAL DESIGN: Immunohistochemical analysis was done on a tissue microarray constructed from paraffin-embedded primary tumor specimens from 357 patients treated by nephrectomy for RCC. Nuclear expression was evaluated by a single pathologist who was blinded to outcome. The expression levels were associated with pathologic variables and survival. RESULTS: HIF-1alpha expression was greater in RCC than in benign tissue. Clear cell RCC showed the highest expression levels. In clear cell RCC, HIF-1alpha was significantly correlated with markers of apoptosis (p21, p53), the mammalian target of rapamycin pathway (pAkt, p27), CXCR3, and proteins of the vascular endothelial growth factor family. HIF-1alpha was correlated with CAIX and CAXII in localized, but not in metastatic RCC. HIF-1alpha expression predicted outcome in metastatic patients: patients with high HIF-1alpha expression (>35%) had significantly worse survival than patients with low expression (

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Publishing Authors By Initials

T Klatte,DB Seligson,SB Riggs,JT Leppert,MK Berkman,MD Kleid,H Yu,FF Kabbinavar,AJ Pantuck,AS Belldegrun,T Klatte,DB Seligson,SB Riggs,JT Leppert,MK Berkman,MD Kleid,H Yu,FF Kabbinavar,AJ Pantuck,AS Belldegrun,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical cancer research : an official journal of

VOLUME: 13

Page Numbers: 7388-93

Journal Abbreviation: Clin. Cancer Res.

ISSN: 1078-0432

DAY: 15

MONTH: Dec

YEAR: 2007

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma.

AFFILIATION: Authors' Affiliations: Departments of Urology, Pathology and Laboratory Medicine, and Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma Related Publications

• A novel resectoscope for transurethral resection of bladder tumors and the prostate.
• Advances in the Treatment of Genitourinary Cancer: Highlights from the 3rd Annual Meeting of the Society of Urologic Oncology, December 13-14, 2002, Washington, DC.
• Biomarkers for early detection and optimized treatment for transitional cell carcinoma.
• Bladder cancer 2000: molecular markers for the diagnosis of transitional cell carcinoma.
• Case scenario: 69-year-old male with left spermatic cord mass.
• Determining the optimal treatment for advanced bladder cancer.
• Hypoxia-Inducible Factor 1{alpha} in Clear Cell Renal Cell Carcinoma.
• Immune and genetic therapies for advanced renal cell carcinoma.
• Immunotherapy and peripheral-blood transplant for metastatic renal cell carcinoma.
• In vivo efficacy of laparoscopic assisted percutaneous renal cryotherapy: evidence based guidelines for the practicing urologist.
• Innovative Strategies Proposed at the Western AUA Meeting: Highlights From the Annual Meeting of the Western Section of the American Urological Association September 26-30, 1999, Monterey, California.
• Laparoscopic and percutaneous ablative techniques in the treatment of renal cell carcinoma.
• Late relapse of germ-cell tumor.
• Lymph node dissection in patients with kidney cancer: when is it indicated?
• Molecular markers for renal cell carcinoma.
• Nephron-sparing surgery for renal cell carcinoma.
• Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer.
• Primary leiomyosarcoma of the inferior vena cava presenting as a renal mass.
• Report from the society of urologic oncology: highlights from the fourth annual meeting of the society of urologic oncology, december 5-6, 2003, bethesda, MD.
• Rethinking staging and treatment for renal cell cancer.
• Salvage cryosurgery of the prostate after radiation failure.
• Surveillance strategies for renal cell carcinoma patients following nephrectomy.
• Synchronous RCC and TCC of the Kidney in a Patient With Multiple Recurrent Bladder Tumors.
• Testicular microlithiasis, chemotherapy for stage I seminoma, and chemotherapy for advanced extragonadal germ cell tumors.
• Therapeutic strategies, predicting outcomes in patients with renal cell and transitional cell carcinomas.
• Thyroid autoantibodies, telomerase activity, vascular endothelial growth factor, and bone scanning.
• Understanding the natural biology of kidney cancer: implications for targeted cancer therapy.
• Update on partial nephrectomy and novel techniques.
• Urologic oncology: extraordinary opportunities for discovery: highlights from the 2nd annual winter meeting of the society of urologic oncology december 1-2, 2001, bethesda, MD.
• Urology in the desert 2000: highlights from the 76th annual meeting of the Western section american urological association.